0000000000142550

AUTHOR

Gianmauro Numico

showing 7 related works from this author

Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary

2020

medicine.medical_specialtyBisphosphonate-associated osteonecrosis of the jawOncology (nursing)business.industryHealth PolicyMEDLINEGuidelinemedicine.diseaseClinical PracticeOncologymascc isoo ascoo mrojHumansMedicineBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawIntensive care medicineJCO Oncology Practice
researchProduct

Sepsis in head and neck cancer patients treated with chemotherapy and radiation: literature review and consensus

2015

Abstract: The reporting of infection/sepsis in chemo/radiation-treated head and neck cancer patients is sparse and the problem is underestimated. A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition and management of infections and sepsis. The Delphi appropriateness method was used for this consensus. External expert reviewers then evaluated the conclusions carefully according to their area of expertise. The paper contains seven clusters of statements about the clinical definition and management of infections and sepsis in head and neck cancer patients, which had a consensus. Furthermore, it offers a revie…

cancer patientpathogenesipositron emission tomographyhealthcare associated infectionSettore MED/06 - Oncologia Medicapatient monitoringradiodiagnosimedicine.medical_treatmentChemotherapy; Head and neck cancer; Radiotherapy; SepsisthrombocytopeniaReviewblood cultureorgan injurymedical terminologyMedicineHead and neck cancermetabolic acidosiC reactive proteinHead and Neck Neoplasmmedical specialisttreatment withdrawalconsensus developmentHematologyclinical practicesystemic inflammatory response syndromeItalyOncologyHead and Neck Neoplasmslaboratory testthrombocytosichemically induced/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingchemotherapy; head and neck cancer; radiotherapy; sepsis; oncology; hematology; geriatrics and gerontologyorgan perfusionhospitalizationHumansepsis Head and Neck Neoplasmmedicine.medical_specialtySettore MED/17 - Malattie InfettiveSepsibacterium culturediagnostic approach routefluorodeoxyglucosecancer chemotherapySepsisSDG 3 - Good Health and Well-beingSepsiscancer radiotherapyfollow upChemotherapyHumansinfection riskIntensive care medicineprocalcitonin antimicrobial therapyChemotherapyRadiotherapybusiness.industrydisease predispositionHead and neck cancerlactic acidChemotherapy; Head and neck cancer; Radiotherapy; Sepsis; Humans; Italy; Head and Neck Neoplasms; Sepsis; Hematology; Oncology; Geriatrics and Gerontologymedicine.diseasemortalityDelphi studyRadiation therapyinflammationincidencehyperglycemiaHuman medicineGeriatrics and Gerontologybusiness
researchProduct

The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma

2009

Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR …

PTENCancer ResearchClass I Phosphatidylinositol 3-KinasesPrognosiSettore MED/06 - Oncologia MedicaColorectal cancerCetuximabColorectal NeoplasmPhosphoinositide 3-kinasemedicine.disease_causePhosphatidylinositol 3-KinasesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansPTENPanitumumabEpidermal growth factor receptorProtein kinase BPI3K/AKT/mTOR pathwayClass I Phosphatidylinositol 3-KinaseAntineoplastic Combined Chemotherapy ProtocolbiologyCetuximabAKTMTORPanitumumabPTEN PhosphohydrolaseAntibodies MonoclonalGeneral MedicinePrognosismedicine.diseaseErbB ReceptorsOncologyMutationbiology.proteinCancer researchReceptor Epidermal Growth FactorKRASPhosphatidylinositol 3-KinaseColorectal NeoplasmsProto-Oncogene Proteins c-aktHumanSignal Transductionmedicine.drug
researchProduct

Update on capecitabine alone and in combination regimens in colorectal cancer patients

2010

Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.

OncologyOrganoplatinum CompoundsOxaloacetatesSettore MED/06 - Oncologia MedicaColorectal cancerLeucovorinCetuximabAdministration OralDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsProdrugsAdjuvantCetuximabAntibodies MonoclonalGeneral MedicineNeoadjuvant TherapyOxaliplatinBevacizumabColorectal carcinomacolon cancerOncologyTolerabilityChemotherapy AdjuvantMetastaticFluorouracilNeoadjuvantColorectal Neoplasmsmedicine.drugDiarrheaAntimetabolites Antineoplasticmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleAdjuvant; Bevacizumab; Capecitabine; Cetuximab; Colorectal carcinoma; Irinotecan; Metastatic; Neoadjuvant; Oxaliplatin; Radiotherapy; Oncology; Radiology Nuclear Medicine and ImagingCapecitabineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingCapecitabineRadiotherapybusiness.industrymedicine.diseaseOxaliplatinClinical trialIrinotecanCamptothecinRadiotherapy AdjuvantbusinessCancer Treatment Reviews
researchProduct

RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw

2016

0301 basic medicinemedicine.medical_specialtyCancer Researchbusiness.industryMedicine (all)Medicine (all); Oncology; Cancer Researchmedicine.diseaseSurgery03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryOncology030220 oncology & carcinogenesisRegorafenibmedicineRegorafenib Osteonecrosis of the JawOsteonecrosis of the jawbusiness
researchProduct

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on La…

2018

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required…

Oncologyosteonecrosimedicine.medical_specialtyONJMRONJ; ONJ; denosumab; jaw; medication-related osteonecrosis of the jaw; multiple myeloma; osteonecrosis; osteonecrosis of the jaw; zoledronic acidMRONJlaw.invention03 medical and health scienceszoledronic acid0302 clinical medicinejawRandomized controlled triallawInternal medicinemedicinemedication-related osteonecrosis of the jawGeneral DentistryMultiple myelomabusiness.industryIncidence (epidemiology)Commentosteonecrosisdenosumab030206 dentistrymedicine.diseaselcsh:RK1-715multiple myelomaosteonecrosis of the jawDenosumabZoledronic acid030220 oncology & carcinogenesislcsh:DentistrybusinessOsteonecrosis of the jawmedicine.drugDentistry journal
researchProduct

Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients

2011

Fluoropyrimidines and oxaliplatin continued to be the mainstay of therapeutic regimens in the treatment of colorectal cancer (CRC). For this reason, pharmacokinetic and metabolism of these drugs were analyzed and the identification of accurate and validated predictive, prognostic and toxicity markers became necessary to develop an effective therapy adapted to the patient's molecular profile, while minimizing life-threatening toxicities. In this review, we discuss literature data, defining predictive and prognostic markers actually identified in the treatment of CRC. We analyzed predictive markers of fluoropyrimidines effectiveness, principally for 5-Fluorouracil (5-FU) and also for oral flu…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerSettore MED/06 - Oncologia Medica5-FluorouracilPredictive markerClinical BiochemistryAntineoplastic AgentsPharmacologyThymidylate synthaseXRCC1Internal medicinemedicineDihydropyrimidine dehydrogenaseBiomarkers TumorHumans5-Fluorouracil; Dihydropyrimidine dehydrogenase; Glutathione S-transferase; Nucleotide excision repair; Oxaliplatin; Predictive marker; Thymidylate Synthase; Toxicity marker; Pharmacology; Clinical BiochemistryPharmacologyPredictive markerbiologyMicrosatellite instabilityThymidylate Synthasemedicine.diseaseToxicity markerOxaliplatinGlutathione S-transferaseOxaliplatinNucleotide excision repairPyrimidinesbiology.proteinERCC1Colorectal NeoplasmsDihydropyrimidine dehydrogenasemedicine.drug
researchProduct